Table 3.
Comparison of medications between patients with MDA5+DM in the survival and non-survival groups
| Non-survival group (N = 32) | Survival group (N = 94) | P-value | |
|---|---|---|---|
| Glucocorticoids only | 12 (37.5) | 16 (17.0) | 0.016 |
| Dual therapy | 16 (50.0) | 58 (61.7) | 0.245 |
| Glucocorticoids + tacrolimus | 5 (15.6) | 31 (33.0) | 0.061 |
| Glucocorticoids + intravenous cyclophosphamide | 7 (21.9) | 24 (25.5) | 0.678 |
| Glucocorticoids + mycophenolate mofetil | 1 (3.1) | 1 (1.1) | 1.000 |
| Glucocorticoids + cyclosporine A | 2 (5.9) | 2 (2.1) | 0.615 |
| Glucocorticoids + thalidomide | 1 (3.1) | 0 (0) | 0.254 |
| Triple therapy | 4 (12.5) | 20 (21.3) | 0.275 |
| Intravenous pulse methylprednisolone | 7 (21.9) | 6 (6.4) | 0.013 |
| Rituximab | 2 (6.3) | 1 (1.1) | 0.322 |
| Tocilizumab | 2 (6.3) | 1 (1.1) | 0.322 |
| Tofacitinib | 0 (0) | 9 (9.6) | 0.110 |
| Intravenous immunoglobulin | 21 (65.5) | 40 (42.6) | 0.024 |
Data presented as number and percentage. Pulse methylprednisolone includes treatment with glucocorticoids alone or glucocorticoids with other immunosuppressants. Triple therapy includes high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide. Bold text highlights the significance
MDA5+DM, anti-MDA5 dermatomyositis